Evidence map›Paper›PMID 31750305›Full record

ArticleFrontiers in medicine2019

Raising to the Challenge: Building a Federated Biobank to Accelerate Translational Research-The University Biobank Limburg.

Loes Linsen, Kimberly Vanhees, Evi Vanoppen, Kim Ulenaers, Suzanne Driessens, Joris Penders, Veerle Somers, Piet Stinissen, Jean-Luc Rummens

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Cytomegalovirus Drives the Development of Cytotoxic CD4Neurology(R) neuroimmunology & neuroinflammation · 2026
    Article
  2. Article
  3. Article
  4. Validation of biomarkers of aging.Nature medicine · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Loes LinsenUniversity Biobank Limburg (UBiLim), Hasselt, Belgium.
Kimberly VanheesUniversity Biobank Limburg (UBiLim), Hasselt, Belgium.
Evi VanoppenUniversity Biobank Limburg (UBiLim), Hasselt, Belgium.
Kim UlenaersUniversity Biobank Limburg (UBiLim), Hasselt, Belgium.
Suzanne DriessensUniversity Biobank Limburg (UBiLim), Hasselt, Belgium.
Joris PendersUniversity Biobank Limburg (UBiLim), Hasselt, Belgium.
Veerle SomersUniversity Biobank Limburg (UBiLim), Hasselt, Belgium.
Piet StinissenUniversity Biobank Limburg (UBiLim), Hasselt, Belgium.
Jean-Luc RummensUniversity Biobank Limburg (UBiLim), Hasselt, Belgium.
Hasselt University · BEJessa Hospital · BEZiekenhuis Oost-Limburg · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irreproducibility of research results is one of the major contributing factors to the failure of translating basic research results into tangible bedside progress. To address this, the University Biobank Limburg (UBiLim) was founded by a collaboration between Hasselt University, the Hospital East-Limburg, and the Jessa Hospital. This paper describes the evolution of this process and the barriers encountered on the way. UBiLim evolved from an archival collection over a single-site biobank into a federated structure, supporting translational research at the founding institutions. Currently, UBiLim is a federated biobank, with an established organizational structure and processing, and storage facilities at each of the three sites. All activities are integrated in an ISO15189-accredited Quality Management System and based on (inter)national biobank guidelines. Common methods for processing and storage of a plethora of sample types, suitable for state-of-the-art applications, were validated and implemented. Because the biobank is embedded in two hospitals, the request of researchers to include certain sample types or enroll specific patient groups can quickly be met. Funding has been a major challenge in each step of its evolution and remains the biggest issue for long-term biobank sustainability. To a lesser extent, the Belgian legislation and the operational cost of information management system are also concerns for smooth biobank operations. Nonetheless, UBiLim serves as a facilitator and accelerator for translational research in the Limburg area of Belgium that, given the fields of research, may have an impact on international patient care.

Indexed as

biobankmulti-disciplinaryqualitytranslational researchUBiLim

Identifiers

PMID31750305
PMCPMC6842921
OpenAlexW2981445042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.